Medicament compositions containing anticholinergically-effective compounds and betamimetics

A pharmaceutical composition comprising:

• (a) an anticholinergic selected from glycopyrronium bromide or an ester of a bi- or tricyclic amino alcohol of formula (I)
• 12
• wherein:
• Q is one of the groups —CH2—CH2—, —CH═CH—, or
• 13
• R is methyl, ethyl, or propyl optionally substituted by fluorine or hydroxy,
• R′ is methyl, ethyl, or propyl, and
• an equivalent of an anion X counters the positive charge of the N atom;
• and
• Z is one of the groups
• 14
• wherein:
• Y is a single bond or an O atom,
• R1 is hydrogen, hydroxy, methoxy, ethoxy, propoxy, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, or hydroxypropyl,
• R2 is a thienyl, phenyl, or cyclohexyl group, wherein these groups are optionally substituted by methyl, and thienyl and phenyl are optionally substituted by fluorine or chlorine, and
• R3 is hydrogen, or a thienyl or phenyl group which is optionally substituted by fluorine, chlorine, or methyl;
• and
• (b) a betamimetic selected from the group consisting of:
• formoterol;
• salmeterol;
• 4-hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulfonyl}ethyl]amino}ethyl ]-2(3H)-benzothiazolone;
• 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino ]ethanol;
• 1-[3-(4-methoxybenzylamino)-4-hydroxyphenyl]-2-[4-( 1-benzimidazolyl)-2-methyl-2-butylamino ]ethanol;
• 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl ]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino ]ethanol;
• 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl ]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol;
• 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl ]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]ethanol;
• and 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazol-3-yl ]-2-methyl-2-butylamino}ethanol, and a pharmacologically compatible acid addition salt thereof.